Etheros Pharmaceuticals

Etheros Pharmaceuticals is a private biotechnology company developing a new class of small molecule drugs based on water-soluble fullerene chemistry. Its compounds are designed as catalytic antioxidants that mimic endogenous protective enzymes such as superoxide dismutase and catalase to reduce oxidative and inflammatory injury, particularly in neural tissue. The company is focused on neuroprotection and broader age-related disease biology, with preclinical evidence spanning cognition, lifespan extension, and multiple animal disease models. Etheros appears to be advancing a platform built around fullerene-derived enzyme mimetics rather than a broad disclosed clinical pipeline. The company is headquartered in Nashville, Tennessee and is backed by longevity-focused investors including Immortal Dragons, VitaDAO, and Healthspan Capital.